Higher PAPP-A Values in Pregnant Women Complicated with Preeclampsia Than with Gestational Hypertension
Tóm tắt
The purpose of this study is to compare the levels of maternal serum pregnancy–associated plasma protein-A at the first trimester in pregnancies complicated by impaired placental diseases, such as preeclampsia (PE), intrauterine fetal growth restriction (IUGR), and gestational hypertension (GH), with those in pregnancies without the development of any of these outcomes to expand the knowledge of how this protein behaves in the different impaired placental diseases. This current work is an observational study based on a prospective cohort. Pregnancy-associated plasma protein-A was measured in 422 patients who had completed maternal-perinatal outcomes. Comparisons of pregnancy characteristics and the biomarker between outcome groups (PE, IUGR, gestational hypertension, and not impaired placental outcomes) were analyzed. PAPP-A MoM in the IUGR (0.8 IQR: 0.6–0.9) and GH groups (0.5 IQR: 0.3–1.4) compared to the PE group (1.06 IQR: 0.66–1.52) was significantly lower (p < 0.005). Pregnant women who developed early-onset PE (1.11 IQR 1.08–1.18) presented significant differences with the IUGR group (0.83 IQR: 0.59–0.98; p = 0.002) and those who developed preterm-PE (1.19 IQR: 0.66–1.58; p = 0.045). The results demonstrate that the levels of PAPP-A at first trimester in the sample of women who developed PE, and specially term-PE, were higher than those in women who developed GH or IUGR. The GH group had the lowest PAPP-A values in this sample of pregnant women. Research in a population with a high prevalence of preeclampsia is still lacking and deserves more extended studies to define if these patients could have different rates of PAPP-A.
Tài liệu tham khảo
Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 1986;93(10):1049–59.
Panaitescu AM, Akolekar R, Kametas N, Syngelaki A, Nicolaides KH. Impaired placentation in women with chronic hypertension who develop pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(4):496–500. https://doi.org/10.1002/uog.17517.
Figueras F, Gratacos E, Rial M, Gull I, Krofta L, Lubusky M, et al. Revealed versus concealed criteria for placental insufficiency in an unselected obstetric population in late pregnancy (RATIO37): randomised controlled trial study protocol. BMJ Open. 2017;7(6):e014835. https://doi.org/10.1136/bmjopen-2016-014835.
Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP, et al. Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014;121(Suppl 1):14–24. https://doi.org/10.1111/1471-0528.12629.
Ray JG, Wanigaratne S, Park AL, Bartsch E, Dzakpasu S, Urquia ML. Preterm preeclampsia in relation to country of birth. J Perinatol. 2016;36(9):718–22. https://doi.org/10.1038/jp.2016.73.
Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens Res. 2017;40(3):213–20. https://doi.org/10.1038/hr.2016.126.
Romero Infante XC, Uriel M, Porras Ramírez A, Rincón FS. Comparison of preeclampsia and fetal growth restriction screenings at first trimester in a high-risk population. J Obstet Gynaecol Res. 2021;47(2):765–73. https://doi.org/10.1111/jog.14605.
Romero Infante XC, Uriel M, Rincón Franco S, Ibáñez Pinilla EA, Rojas NA. First trimester placental growth factor in maternal blood and placenta related disorders. J Matern Fetal Neonatal Med. 2021;1:1–8. https://doi.org/10.1080/14767058.2021.1960966.
Guzmán YN, Uriel M, Ramírez AP, Romero XC. Uterine artery pulsatility index as a pre-eclampsia predictor in the 3 trimesters in women with singleton pregnancies. Rev Bras Ginecol Obstet. 2021;43(12):904–10. https://doi.org/10.1055/s-0041-1740273. (English).
Gutiérrez Ardila A, Uriel M, Rico Mendoza FA, Romero Infante XC. Prevalencia de morbilidad materna extrema en unidad de cuidados intensivos de una institución prestadora de servicios de salud de tercer nivel en Bogotá D.C. Acta Colombiana de Cuidado Intensivo. 2022;22(2):81–87. https://doi.org/10.1016/j.acci.2021.04.003.
Magee LA, Nicolaides KH, von Dadelszen P. Preeclampsia. N Engl J Med. 2022;386(19):1817–32. https://doi.org/10.1056/NEJMra2109523.
Herrera JA, Herrera-Medina R, Herrera-Escobar JP, Nieto-Díaz A. Reduction of maternal mortality due to preeclampsia in Colombia–an interrupted time-series analysis. Colomb Med (Cali). 2014;45(1):25–31 (eCollection 2014 Jan-Mar).
Romero XC, Gutiérrez AM, Rojas NA, Ramírez A, Aldana J, Eslava M, Pérez BD, Forero CA, Uriel M, Camacho Rodríguez B. Incidence of hypertensive disorders in pregnancy and clinical demographic characteristics in pregnant women in three institutions in Bogotá, D. C., Colombia. Investig Segur Soc Salud. 2018;20(2):21–30.
Antwi E, Amoakoh-Coleman M, Vieira DL, Madhavaram S, Koram KA, Grobbee DE, Agyepong IA, Klipstein-Grobusch K. Systematic review of prediction models for gestational hypertension and preeclampsia. PLoS One. 2020;15(4):e0230955. https://doi.org/10.1371/journal.pone.0230955.
Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, McAuliffe F, da Silva Costa F, von Dadelszen P, McIntyre HD, Kihara AB, Di Renzo GC, Romero R, D’Alton M, Berghella V, Nicolaides KH, Hod M. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Suppl 1):1–33. https://doi.org/10.1002/ijgo.12802.
Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH. Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29(8):753–60. https://doi.org/10.1002/pd.2279.
Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein-A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87(4):1762–7.
Staboulidou I, Galindo A, Maiz N, Karagiannis G, Nicolaides KH. First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects. Fetal Diagn Ther. 2009;25(3):336–9. https://doi.org/10.1159/000235880.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks. Ultrasound Obstet Gynecol. 2010;35(6):662–70. https://doi.org/10.1002/uog.7628.
Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol. 2009;33(1):23–33. https://doi.org/10.1002/uog.6280.
Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11–13 weeks. Prenat Diagn. 2010;30(3):216–23. https://doi.org/10.1002/pd.2440.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11–13 weeks. Fetal Diagn Ther. 2013;33(1):16–27. https://doi.org/10.1159/000341712.
Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol. 2008;31(1):15–9.
O’Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC. Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open. 2016;6(6):e011801. https://doi.org/10.1136/bmjopen-2016-011801.
Poon LC, Karagiannis G, Leal A, Romero XC, Nicolaides KH. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11–13 weeks. Ultrasound Obstet Gynecol. 2009;34(5):497–502. https://doi.org/10.1002/uog.7439.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8–15. https://doi.org/10.1159/000341264.
Tan MY, Koutoulas L, Wright D, Nicolaides KH, Poon LCY. Protocol for the prospective validation study: “Screening programme for pre-eclampsia” (SPREE). Ultrasound Obstet Gynecol. 2017;50(2):175–9. https://doi.org/10.1002/uog.17467.
Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005;25(10):949–53.
Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH. Contingent screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2016;47(5):554–9. https://doi.org/10.1002/uog.15807.
O’Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, et al. Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation. Ultrasound Obstet Gynecol. 2017;49(6):751–5. https://doi.org/10.1002/uog.17399.
Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–31. https://doi.org/10.1097/01.AOG.0000437382.03963.88.
Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97–104. https://doi.org/10.1016/j.preghy.2014.02.001.
Figueras F, Gardosi J. Intrauterine growth restriction: new concepts in antenatal surveillance, diagnosis, and management. Am J Obstet Gynecol. 2011;204(4):288–300. https://doi.org/10.1016/j.ajog.2010.08.055.
Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012). Am J Obstet Gynecol. 2020;223(4):B2–17. https://doi.org/10.1016/j.ajog.2020.05.010.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. https://doi.org/10.1001/jama.2013.281053.
Resolución 8430 de 1993. Bogotá D.C. (Colombia) República de Colombia Ministerio de Salud. 1993. https://minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.pdf.
Hoseini MS, Sheibani S, Sheikhvatan M. The evaluating of pregnancy-associated plasma protein-A with the likelihood of small for gestational age. Obstet Gynecol Sci. 2020;63(3):225–30. https://doi.org/10.5468/ogs.2020.63.3.225.
Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, Rey E. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol. 2010;203(4):383.e1-8. https://doi.org/10.1016/j.ajog.2010.06.014.
Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51(6):743–50. https://doi.org/10.1002/uog.19039.
O’Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(6):756–60.
Birdir C, Droste L, Fox L, Frank M, Fryze J, Enekwe A, et al. Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy. Pregnancy Hypertens. 2018;12:124–8. https://doi.org/10.1016/j.preghy.2018.04.010.
Saruhan Z, Ozekinci M, Simsek M, Mendilcioglu I. Association of first trimester low PAPP-A levels with adverse pregnancy outcomes. Clin Exp Obstet Gynecol. 2012;39(2):225–8.
Skråstad RB, Hov GG, Blaas HG, Romundstad PR, Salvesen KÅ. A prospective study of screening for hypertensive disorders of pregnancy at 11–13 weeks in a Scandinavian population. Acta Obstet Gynecol Scand. 2014;93(12):1238–47. https://doi.org/10.1111/aogs.12479.
Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53(5):812–8. https://doi.org/10.1161/HYPERTENSIONAHA.108.127977.
Park FJ, Leung CH, Poon LC, Williams PF, Rothwell SJ, Hyett JA. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Aust N Z J Obstet Gynaecol. 2013;53(6):532–9. https://doi.org/10.1111/ajo.12126.
Sonek J, Krantz D, Carmichael J, Downing C, Jessup K, Haidar Z, et al. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume. Am J Obstet Gynecol. 2018;218(1):126.e1-126.e13. https://doi.org/10.1016/j.ajog.2017.10.024.
Rolnik DL, Wright D, Poon LCY, Syngelaki A, O’Gorman N, de Paco MC, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(4):492–5. https://doi.org/10.1002/uog.18816.
Vallejo GM, Uriel M, Porras-Ramírez A, Romero XC. Could aspirin treatment modify the assessment of the uterine arteries? Rev Bras Ginecol Obstet. 2022;44(3):231–7. https://doi.org/10.1055/s-0042-1742411. (English).